To Evaluate the Outcome of Use of Inhalers in Patient with Chronic Obstructive Pulmonary Disease (COPD) Following Training
Background: Chronic obstructive pulmonary disease (COPD) is a common respiratory condition associated with high morbidity and mortality. A correct diagnosis of COPD can decrease symptoms, reduce frequency and severity of exacerbations, improve health status, improve exercise capacity, and prolong survival. Inhaler devices are mainstay in management of chronic obstructive pulmonary disease and their proper usage requires continuous training. A thorough literature search has shown limited data on the outcome of various techniques and devices used in COPD; hence this study is being done to study the outcome of use of inhalers in patients with COPD following training.
Methods: This prospective, observational study was conducted on patients suffering from COPD as per Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. The patients were given instructions and training correctly all patients were called after one month and spirometry parameters were assessed after one month. Spirometry and St. George Respiratory Questionnaire was administered to all participants.
Results: A total of 60 patients were enrolled in study with the mean age of 49.37±17.65 years. 19 patient suffering from COPD also had concurrent diseases associated. Revolizer was used by 60% of patients. There was a significant (p<0.05) improvement in FEV1 and PEF after 1 month of proper use of inhalation technique. All patients showed a statistically significant (p<0.05) improvement in symptoms score in SGRQ.
Conclusion: A significant improvement in FEV1, Ratio of FEV1/FVC and PEF was observed after 1 month, there was also improvement in Quality of life of patients.
2. Gershon AS, Warner L, Cascagnette P, et al. Lifetime risk of developing chronic obstructive pulmonary disease: A longitudinal population study. Lancet 2011; 378:991.
3. Centres for Disease Control and Prevention (CDC).Chronic obstructive pulmonary disease among adults--United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:938.
4. Miniño AM, Murphy SL, Xu J, Kochanek KD. Deaths: Final data for 2008. Natl Vital Stat Rep 2011; 59:1.
5. Global Strategy for the Diagnosis Management and Prevention of COPD Global initiative for chronic obstructive lung disease (GOLD) 2014. Available from: http://www.goldcopd.org/ [Last Accessed January 15, 2017].
6. Wright J, Brocklebank D, Ram F. Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD). Qual Saf Health Care. 2002; 11: 376–82.
7. Dolovich MB, Ahrens RC, Hess DR, et.al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335–71.
8. Newman SP. Inhaler treatment options in COPD. Eur Respir Rev 2005; 14: 102–8.
9. Jones PW, Quirk FH, Baveystock CM. The St. George’s Respiratory Questionnaire. Respir Med 1991; 85: 25-31
10. Molimard M, Colthorpe P. Inhaler devices for chronic obstructive pulmonary disease: insights from patients and healthcare practitioners. J Aerosol Med Pulm Drug Deliv. 2014. [Epub ahead of print].
11. Lavorini F, Levy ML, Corrigan C, Crompton G, ADMIT Working Group. The ADMIT series– issues in inhalation therapy. Training tools for inhalation devices. Prim Care Respir J 2010; 19: 335–41.
12. Fink JB, Rubin BK. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005; 50: 1360–74.
13. Hodder R, Price D. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis 2009; 4: 381–90.